Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
OBJECTIVE
Breast and prostate cancer are amongst the most prevalent malignancies globally and up to 40% of patients will develop metastatic disease, particularly to the skeleton. Multiple myeloma is the most common cancer to affect bone with up to 90% of patients developing bone lesions. Although several studies demonstrated that endocrine changes such as vitamin D deficiency promote secondary cancer growth in bone, relatively few have reported its prevalence. For this reason, the purpose of the present study was to evaluate the prevalence of hypovitaminosis D in patients with bone metastases and multiple myeloma.


METHODS
Serum 25-OH-D levels of patients with metastatic bone disease were measured on admission. Statistical analyses was performed to evaluate for possible confounders of hypo-vitaminosis D.


RESULTS
We found a widespread and alarming rate of vitamin D deficiency in patients with metastatic bone disease and multiple myeloma. Of note, patients with bone metastases due to breast cancer, prostate cancer and multiple myeloma rarely reached sufficient serum 25-OH-D levels.


CONCLUSIONS
It is of utmost clinical importance to assess vitamin D levels in cancer patients, especially in those with, or at high risk of developing metastatic bone disease.
University Hospital of Orthopaedic Surgery, Pius-Hospital, Carl-von-Ossietzky-University, Oldenburg, Germany gerrit.maier@uni-oldenburg.de.
Gerrit Steffen
GS
Maier
ANZAC Research Institute, University of Sydney at Concord, Sydney, NSW, Australia.
Konstantin
K
Horas
Department of Orthopaedic Surgery, Themistocles Gluck Hospital, Ratingen, Germany.
Andreas Alois
AA
Kurth
University Hospital of Orthopaedic Surgery, Pius-Hospital, Carl-von-Ossietzky-University, Oldenburg, Germany.
Djordje
D
Lazovic
Department of Orthopaedic Surgery, Justus-Liebig-University, Giessen, Germany.
Jörn Bengt
JB
Seeger
University Hospital of Orthopaedic Surgery, Pius-Hospital, Carl-von-Ossietzky-University, Oldenburg, Germany.
Uwe
U
Maus
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000473:pathology*; D010281:Parathyroid Hormone / Q000097:blood; D015995:Prevalence; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology*; D012307:Risk Factors; D014807:Vitamin D / Q000097:blood*; D014808:Vitamin D Deficiency / Q000097:blood / Q000453:epidemiology* / Q000209:etiology
D010281:Parathyroid Hormone; D014807:Vitamin D
Vitamin D deficiency; bone cancer; bone metastases; bone tumor; vitamin D